ERBB2 and renal pelvis/ureter urothelial carcinoma: Previous studies showed that micropapillary and sarcomatoid variants were associated with poorer oncological outcomes, and molecular markers such as human epidermal growth factor receptor−2 (HER2) is considered to be a potential prognostic and therapeutic marker in patients with upper tract urothelial carcinoma (21, 22).